The SELECT cardiovascular outcomes trial published in 2023 added a cardiovascular benefit signal: semaglutide reduced major adverse cardiovascular events by 20% in overweight and obese patients with established cardiovascular disease, independent of diabetes status
Both exenatide and liraglutide are relatively well tolerated, with dose-dependent nausea, vomiting, and diarrhea being the most commonly reported adverse events observed in clinical trials
This patient approach matters more than most people realize
This gap between demand and accessible supply creates perfect conditions for scammers
Hims & Hers, along with countless other telemedicine companies, including Ro, also sold compounded tirzepatide
But also more unknowns, more potential side effects, and no current legal pathway to access